Pegylated liposomal doxorubicin (Doxil) is a standard chemotherapy drug used to treat ovarian cancer that has continued to grow or has returned after therapy that included a platinum-containing drug. However, in some patients the cancer continues to grow. Doctors are therefore seeking more effective treatments for this cancer.
Vintafolide (EC145) is an investigational drug composed of folic acid — which attaches to folate receptors on cancer cells — and vinca, a chemotherapy drug which kills cancer cells. In this study, researchers want to see if giving Doxil with vintafolide is more effective for treating platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer than Doxil alone.
Patients will be randomly assigned to receive Doxil plus vintafolide or Doxil plus a placebo (inactive liquid). Each treatment is given intravenously (by vein). In addition to treatment effectiveness, researchers will also be looking at the effects of therapy on patients’ quality of life.